AGIOS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.03% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-02-12
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-09-30 was 1.28%, a 26.01% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-06-30 was 1.38%, a 19.30% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-03-31 was 1.42%, a 16.96% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-09-30 was 1.73%, a 11.28% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.03%, a 2.89% decline from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.15%, a 2.47% increase from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.05%, a 58.82% increase from fiscal 2022.
- AGIOS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.55%, a 254.17% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.03% 10-K · filed 2026-02-12 | |||
| 2024-12-31 | 4.15% 10-K · filed 2026-02-12 | |||
| 2023-12-31 | 4.05% 10-K · filed 2026-02-12 | |||
| 2022-12-31 | 2.55% 10-K · filed 2025-02-13 | |||
| 2021-12-31 | 0.72% 10-K · filed 2024-02-15 | |||
| 2020-12-31 | 1.24% 10-K · filed 2023-02-23 | |||
| 2019-12-31 | 2.32% 10-K · filed 2022-02-24 | |||
| 2018-12-31 | 2.71% 10-K · filed 2021-02-25 | |||
| 2017-12-31 | 2.05% 10-K · filed 2020-02-19 | |||
| 2016-12-31 | 1.42% 10-K · filed 2019-02-14 | |||
| 2016-09-30 | 1.28% 10-Q · filed 2016-11-03 | 1.39% 10-Q · filed 2016-11-03 | ||
| 2016-06-30 | 1.38% 10-Q · filed 2016-08-08 | 1.41% 10-Q · filed 2016-08-08 | ||
| 2016-03-31 | 1.42% 10-Q · filed 2016-05-09 | |||
| 2015-12-31 | 1.71% 10-K · filed 2018-02-14 | |||
| 2015-09-30 | 1.73% 10-Q · filed 2016-11-03 | 1.71% 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | 1.71% 10-Q · filed 2016-08-08 | 1.71% 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | 1.71% 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | 1.83% 10-K · filed 2017-02-16 | |||
| 2014-09-30 | 1.95% 10-Q · filed 2015-11-06 | 1.83% 10-Q · filed 2015-11-06 | ||
| 2014-06-30 | 1.81% 10-Q · filed 2015-08-07 | 1.82% 10-Q · filed 2015-08-07 | ||
| 2014-03-31 | 1.82% 10-Q · filed 2015-05-11 | |||
| 2013-12-31 | 1.31% 10-K · filed 2016-02-26 | |||
| 2013-09-30 | 1.73% 10-Q · filed 2014-11-07 | 1.23% 10-Q · filed 2014-11-07 | ||
| 2013-06-30 | 1.00% 10-Q · filed 2014-08-07 | 1.00% 10-Q · filed 2014-08-07 | ||
| 2012-12-31 | 1.09% 10-K · filed 2015-02-24 | |||
| 2012-09-30 | 0.82% 10-Q · filed 2013-11-07 | 1.12% 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | 1.18% 10-Q · filed 2013-09-05 | 1.13% 10-Q · filed 2013-09-05 | ||
| 2011-12-31 | 1.97% 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |